In Vivo Liver-Directed Gene Editing to Treat Highly Prevalent & Life-Threatening Disease

Time: 9:30 am
day: Day Two


• Outlining program to safely and durably turn off genes in the liver
• Managing the challenges of assessing human-directed therapies in non-human pre-clinical studies
• Expanding to other indications to achieve to true “in vivo” potential